Calcified Tissue International

, Volume 57, Issue 6, pp 405–408 | Cite as

25 Years of salmon calcitonin: From synthesis to therapeutic use

  • M. Azria
  • D. H. Copp
  • J. M. Zanelli


Although calcitonin has an established place in the treatment of Paget's disease of bone and certain disorders of calcium homeostasis, its most exciting clinical application is in the management of postmenopausal and senile osteoporosis. This disorder affects a vast number of women and, with the increasingly aging population, imposes a heavy burden on health care systems. Although other therapies for osteoporosis and other disorders of bone turnover (e.g., bisphosphonates, fluoride) are in use, many questions remain to be answered concerning their side effects and long-term safety, whereas salmon calcitonin is of proven safety. The introduction of salmon calcitonin nasal spray is a significant therapeutic advance, and the development of other noninjectable preparations will further increase the acceptability of calcitonin to patients and physicians alike.


Osteoporosis Fluoride Clinical Application Health Care System Bisphosphonates 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Copp DH (1994) Calcitonin: discovery, development, and clinical application. Clin Invest Med 17:268–277Google Scholar
  2. 2.
    Azria M (1989) The calcitonins: physiology and pharmacology. Karger, BaselGoogle Scholar
  3. 3.
    Copp DH, Davidson AGF, Cheney BA (1961) Evidence for a new parathyroid hormone which lowers blood calcium. Proc Can Fed Biol Soc 4:17Google Scholar
  4. 4.
    Copp DH, Cameron EC, Cheney B, Davidson AGF, Henze K (1962) Evidence for calcitonin—a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638–649Google Scholar
  5. 5.
    Kumar MA, Foster GV, MacIntyre I (1963) Further evidence for calcitonin—a rapid acting hormone which lowers blood calcium. Lancet ii:480–482Google Scholar
  6. 6.
    Hirsch PF, Gauthier GF, Munson PL (1963) Thyroid hypocalcemic principle and recurrent laryngeal nerve injury as factors affecting the response to parathyroidectomy in rats. Endocrinology 73:244–252Google Scholar
  7. 7.
    Pearse AGE, Carvalheira AF (1967) Cytochemical evidence for an ultimobranchial origin of rodent thyroid C cells. Nature 214:929–930Google Scholar
  8. 8.
    Copp DH, Cockcroft DW, Kueh Y (1967) Calcitonin from the ultimobranchial glands of dogfish and chickens. Science 158:924–926Google Scholar
  9. 9.
    O'Dor RK, Parkes CO, Copp DH (1969) Amino acid composition of salmon calcitonin. Can J Biochem 47:823–825Google Scholar
  10. 10.
    Niall JT, Keutmann HT, Copp DH, Potts JT Jr (1969) Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci USA 63:771–778Google Scholar
  11. 11.
    Guttmann S, Pless J, Huguenin RL, Sandrin E, Bossert H, Zehnder K (1969) Synthese von Salm-Calcitonin, einem hochaktiven hypocalcämischen Hormon. Helv Chim Acta 52:1789–1795Google Scholar
  12. 12.
    Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819–824Google Scholar
  13. 13.
    Wallach S, Farley JR, Baylink DJ, Brenner-Gati L (1993) Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 52:335–339Google Scholar
  14. 14.
    Geusens P, Nijs J, Jiang Y, Caulin F, Van Audekercke R, Van der Perre G, Goovaerts S, Gielen J, Marchal G, Dequeker J (1990) Bone mass, density and strength in ovariectomized sheep treated with salmon calcitonin. In: Christiansen C, Overgaard K (ed) Osteoporosis 1990. Osteopress ApS, Copenhagen, pp 1152–1153Google Scholar
  15. 15.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305:556–561Google Scholar
  16. 16.
    Zanelli JM, Gaines-Das RE, Corran PH (1990) International Standards for salmon calcitonin and the ASU 1–7 analogue of eel calcitonin: calibration by international collaborative study. Bone Miner 11:1–17Google Scholar
  17. 17.
    Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 23:1148–1154Google Scholar
  18. 18.
    Patel S, Lyons AR, Hosking DJ (1993) Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs 46:594–617Google Scholar
  19. 19.
    Sjöberg HE, Hjern B (1975) Acute treatment with calcitonin in primary hyperparathyroidism and severe hypercalcaemia of other origin. Acta Chir Scand 141:90–95Google Scholar
  20. 20.
    Nishi Y, Hamamoto K, Kajiyama M, Ono H, Kihara M, Jinno K (1992) Effect of long-term calcitonin therapy, by injection and nasal spray on the incidence of fractures in osteogenesis imperfecta. J Pediatr 121 (3): 477–480Google Scholar
  21. 21.
    Doury P, Dirheimer Y, Pattin S (1981) Algodystrophy: diagnosis and therany of a frequent disease of the locomotor apparatus. Springer, Berlin, Heidelberg, New YorkGoogle Scholar
  22. 22.
    di Perry T, Auteri A, Bruni F, Blardi P, Vannucchi F (1985) Calcitonin treatment for rheumatoid arthritis: a controlled clinical study. In: Pecile A (ed) Calcitonin 1984. Excerpta Medica, Amsterdam, pp 307–314Google Scholar
  23. 23.
    Miralles FS, Lopez-Soriano F, Puig MM, Perez D, Lopez-Rodriguez F (1987) Postoperative analgesia induced by subarachnoid lidocaine plus calcitonin. Anesth Analg 66:615–618Google Scholar
  24. 24.
    Becker HD, Reeder DD, Scurry MT, Thompson JC (1974) Inhibition of gastrin release and gastric secretion by calcitonin in patients with peptic ulcer. Am J Surg 127:71–75Google Scholar
  25. 25.
    Goebell H, Hotz J (1981) Calcitonin, pancreatic secretion and pancreatitis. In: Pecile A (ed) Calcitonin 1980. Excerpta Medica, Amsterdam, pp 346–351Google Scholar
  26. 26.
    Franchi F, Chiarini P, Matassi L, Strazzulla G, Scardi A, Righi D, Nuzzaci D (1983) Effect of calcitonin on limb blood vessels in human obstructive arterial disease. Int J Clin Pharm Res 111 (2):115–128Google Scholar
  27. 27.
    Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989a) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 299:477–479Google Scholar
  28. 28.
    Reginster JYL, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I (1995) A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumber spine bone loss. Am J Med 98:452–458Google Scholar
  29. 29.
    Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989b) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435–442Google Scholar
  30. 30.
    Mazzuoli GF, Tabolli S, Bigi F, Vatorta C, Diacinti D, Scarnecchia L, Minisola S, Bianchi G, Piolini M, Dell' Acqua S (1989) Effects of salmon calcitonin on loss of bone mass induced by ovariectomy: controlled double-blind study. In: Mazzuoli GF (ed) Calcitonin ′88. Proc Int Symp. Sandoz Ltd, Basel, pp 15–24Google Scholar
  31. 31.
    Overgaard K, Hansen MA, Nielsen VAH, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment. Am J Med 89:1–6Google Scholar
  32. 32.
    Minaire P, Mallet E, Levernieux J, Schoutens A, Attali G, Caulin F (1987) Immobilization bone loss: preventive effects of calcitonin in several models. In: Christiansen C, Johansen JC, Riis BJ (eds) Osteoporosis 1987. Osteopress ApS, Copenhagen pp 603–610Google Scholar
  33. 33.
    Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35–39Google Scholar
  34. 34.
    Ringe JD (1990) Intranasal salmon calcitonin in the treatment of steroid-induced osteoporosis. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress ApS. Copenhagen, pp 1868–1871Google Scholar
  35. 35.
    Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopez Vas AA, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribor C (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:1124–1128Google Scholar
  36. 36.
    Rico H, Hernandez ER, Revilla M, Gomez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131–138Google Scholar
  37. 37.
    Pun KK, Chan LWL (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205–209Google Scholar
  38. 38.
    Gennari C, Agnusdei D, Camporeale A (1991) Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49 (suppl 2):S9–13Google Scholar
  39. 39.
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268–1274Google Scholar
  40. 40.
    Gennari C, Passeri M, Chierichetti SM, Piolini M (1983) Side effects of synthetic salmon and human calcitonin. Lancet i:594–595Google Scholar
  41. 41.
    Clissold SP, Fitton A, Chrisp P (1991) Intranasal salmon calcitonin: a review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1:405–423Google Scholar
  42. 42.
    Singer FR, Alfred JP, Neer AM, Krane SM, Potts JT, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2338Google Scholar
  43. 43.
    Martin TJ (1979) Treatment of Paget's disease with calcitonins. Aust NZ J Med 9:36–43Google Scholar
  44. 44.
    Reginster JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JL, Collette J, Franchimont P (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83–86Google Scholar
  45. 45.
    Mazzuoli GF, Minisola S, Tabolli S, Valtorta C (1983) Il fenomeno escape e plateau. In: Gennari C, Segre G (eds) The effects of calcitonin in man. Proc 1 st Int Workshop, 1982, Masson, pp 75–84Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1995

Authors and Affiliations

  • M. Azria
    • 1
  • D. H. Copp
    • 2
  • J. M. Zanelli
    • 3
  1. 1.R & D DivisionSandoz Pharma LtdBaselSwitzerland
  2. 2.Department of Physiology Faculty of MedicineUniversity of British ColumbiaCanada
  3. 3.Division of EndocrinologyNational Institute for Biological Standards and ControlUnited Kingdon

Personalised recommendations